Source: Health Products Regulatory Authority (ZA) Revision Year: 2022 Publisher: Adcock Ingram Limited, 1 New Road, Erand Gardens, Midrand, 1685, South Africa 0860 ADCOCK (232625)
Pharmacotherapeutic group: A.18 Medicines acting on genito-urinary system
ATC code: G04BD02
Flavoxate hydrochloride is a non-specific, direct-acting, smooth muscle relaxant.
It acts by inhibiting cAMP-dependent phosphodiesterase, thus producing a cAMP accumulation that reduces the efficiency of the calcium messenger system during smooth muscle contraction. The compound exhibits only weak affinity for α- and β-adrenergic receptors involved either directly or indirectly in voiding.
At active doses with myolitic effects, flavoxate does not influence the parasympathetic system and does not cause any vagolytic-like effects.
Recent findings suggest that it may also act on the micturition center.
Flavoxate is readily adsorbed from the gut, enters the blood, and concentrates rapidly in the tissues where it is metabolized into 3- methylflavon-8carboxylic acid. This metabolite is excreted with the urine partly unmodified and partly conjugated as glucoronide.
Urinary excretion takes place within 4 to 6 hours from administration.
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, and toxicity to reproduction and development. Carcinogenicity studies have not been performed.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
